港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

483.155

-13.603-2.74%

漲家數：7

跌家數：23

平家數：3

市盈率：- -

高：496.758

開：496.758

低：480.328

收：496.758

成交量：1.15億

成交額：26.12億

市值：3,069.30億

流通市值：2,732.98億

資料載入中...

德琪醫藥－Ｂ(06996)股價下跌8.406%，現價港幣$3.16

阿斯达克财经

亞盛醫藥(06855)股價下跌5.028%，現價港幣$30.98

阿斯达克财经

港股異動 | 同源康醫藥-B(02410)升逾9% 董事長增持彰顯長期發展信心創新EGFR-TKI 重磅獲批

啓明醫療(02500.HK)折讓近11%配股兼發可換股債券料籌5億人幣

阿斯达克财经

科濟藥業-B盤中漲近5% 公司香港業務取得重要進展

港股異動 | 科濟藥業-B(02171.HK)早盤漲近5% 香港業務取得重要進展進一步推進愷力美國際化佈局

和鉑醫藥－Ｂ(02142)股價下跌5.004%，現價港幣$13.48

阿斯达克财经

港股異動 | 先健科技(01302)升逾3% LantvalTM主動脈瓣膜置換系統進入創新醫療器械特別審查程序

【券商聚焦】中信建投：醫療器械板塊業績有望逐步改善

深港攜手拓全球藥械市場，2026深圳國際高性能醫療器械展舉行

【券商聚焦】中信證券：上半年CXO及生命科學上游板塊整體表現穩健，CRO有望量價齊升

歸創通橋(02190)出現大手買入85萬股，成交價$23.4，涉資1.989千萬

阿斯达克财经

涉IPO操縱嫌疑，香港證監會強制眼科創新藥公司撥康視雲停牌，最牛天使投資人富豪龔虹嘉是站台的基石投資者

國產創新藥新適應症密集獲批「一藥拓多域」重塑行業成長邏輯

歐康維視生物-B：OT-301（NCX 470，比馬前列素格倫諾）在華上市申請獲國家藥監局受理

歐康維視生物-B(01477)：OT-301新藥上市註冊申請獲國家藥品監督管理局受理

第七批國家組織醫用耗材集中採購開標；諾華大股東呼籲改組董事會｜醫藥早參

每日经济新闻

勁方醫藥-B(02595.HK)9月10日斥資206.3萬港元回購8萬股

啓明醫療(02500)發新股及換股債集資5億人民幣

阿斯达克财经

同源康醫藥-B(02410.HK)獲董事長吳豫生增持63.5萬股H股涉資約209萬港元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BK1574/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":483.15506,"timestamp":1789114133774,"preClose":496.75812,"halted":0,"volume":115323363,"delay":0,"changeRate":-0.027384,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-13.603058,"latestTime":"09-11 16:00:00","open":496.75812,"high":496.75812,"low":480.32812,"amount":2611810568,"amplitude":0.033074,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":3.606253,"peRate":160.422718,"turnoverRate":0.004215,"increases":6,"decrements":25,"flats":1,"marketCap":306930068880,"floatMarketCap":273297591592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":496.75812,"amplitude":0.033074,"preClose":496.75812,"low":480.32812,"pbRate":"3.606253","latestPrice":483.15506,"volume":115323363,"delay":0,"open":496.75812,"prevYearClose":556.26263,"prevWeekClose":532.025,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":532.025,"twentyDayClose":518.327,"sixtyDayClose":434.471,"secType":"PLATE","market":"HK","turnoverRate":0.004215,"peRate":160.422718,"marketCap":306930068880,"floatMarketCap":273297591592,"timestamp":1789114133774,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":23,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666485825","title":"德琪醫藥－Ｂ(06996)股價下跌8.406%，現價港幣$3.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2666485825","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666485825?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 11:14","pubTimestamp":1789096440,"startTime":"0","endTime":"0","summary":"[下跌股]德琪医药－Ｂ(06996) 股价在上午11:13比前收市价下跌8.406%，现股价为港币$3.16。至目前为止，今日最高价为$3.5，而最低价为$3.16。总成交量为61.25万股，总成交金额为港币$198.37万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609112316/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609112316/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","06996","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666548304","title":"亞盛醫藥(06855)股價下跌5.028%，現價港幣$30.98","url":"https://stock-news.laohu8.com/highlight/detail?id=2666548304","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666548304?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 11:12","pubTimestamp":1789096320,"startTime":"0","endTime":"0","summary":"[下跌股]亚盛医药(06855) 股价在上午11:12比前收市价下跌5.028%，现股价为港币$30.98。至目前为止，今日最高价为$32.48，而最低价为$30.98。总成交量为147.737万股，总成交金额为港币$4.663千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135511023_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135511023_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609112308/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609112308/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510406","title":"港股異動 | 同源康醫藥-B(02410)升逾9% 董事長增持彰顯長期發展信心 創新EGFR-TKI 重磅獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510406","media":"智通财经","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666510406?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 11:01","pubTimestamp":1789095677,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B今早拉升逾9%，截至发稿，涨9.7%，报2.94港元，成交额963.22万港元。消息面上，同源康医药昨晚公布，董事长、执行董事兼总裁吴豫生告知，于本月8至10日期间，于公开市场购入63.5万股H股，占已发行股本总额约0.17%，总代价约209万港元。公司表示，吴豫生已告知未来可能继续根据市场情况购买股份。此次进一步增持股份彰显对集团未来发展前景的信念及充分信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","VXUS","159938","02410","BK4588","BK1161","BK4585","BK1574","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666101235","title":"啓明醫療(02500.HK)折讓近11%配股兼發可換股債券  料籌5億人幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2666101235","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666101235?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 10:50","pubTimestamp":1789095000,"startTime":"0","endTime":"0","summary":"启明医疗公布，于昨日交易时段后，与认购人杭州盈智勤(参)号股权投资合伙企业订立协议，将配发1.85亿股待认购股份及本金额不超过3.797亿港元的可转换债券。可转换债券初步转换价为每股转换股份1.1858港元，较前交易日收市价每股1.170港元折让2%。认购事项项下投资总额不超过5亿元人民币，公司拟将所得款项净额用于支付研发、临床及监管费用；补充一般企业营运资金；及偿还未偿还贷款。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201222151856754_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201222151856754_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543983/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543983/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","02500","BK1583","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666510692","title":"科濟藥業-B盤中漲近5% 公司香港業務取得重要進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2666510692","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666510692?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 10:42","pubTimestamp":1789094520,"startTime":"0","endTime":"0","summary":"模拟交易客户端科济药业-B盘中涨近5%。科济药业宣布，公司在香港地区的先进疗法产品相关业务取得重要进展，已获得开展相关药剂制品批发供应业务所需的许可资质。此次许可的取得，是科济药业推进恺力美国际化布局的重要里程碑，为公司进一步探索恺力美在香港地区的患者可及路径及相关业务开展奠定了基础，也为公司持续拓展海外市场积累了重要经验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-11/doc-inirmmnc5377838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1587","BK1585","02171","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666517233","title":"港股異動 | 科濟藥業-B(02171.HK)早盤漲近5% 香港業務取得重要進展 進一步推進愷力美國際化佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2666517233","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666517233?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 10:12","pubTimestamp":1789092731,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02171","BK1574","BK1587","BK1585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666457517","title":"和鉑醫藥－Ｂ(02142)股價下跌5.004%，現價港幣$13.48","url":"https://stock-news.laohu8.com/highlight/detail?id=2666457517","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666457517?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:55","pubTimestamp":1789091700,"startTime":"0","endTime":"0","summary":"[下跌股]和铂医药－Ｂ(02142) 股价在上午09:54比前收市价下跌5.004%，现股价为港币$13.48。至目前为止，今日最高价为$14.01，而最低价为$13.48。总成交量为276.1万股，总成交金额为港币$3.859千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609111606/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609111606/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","BK1574","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666517543","title":"港股異動 | 先健科技(01302)升逾3% LantvalTM主動脈瓣膜置換系統進入創新醫療器械特別審查程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2666517543","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666517543?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:49","pubTimestamp":1789091380,"startTime":"0","endTime":"0","summary":"消息面上，先健科技发布公告，于2026年9月9日，本公司收到国家药品监督管理局的正式书面通知，确认由本公司附属公司深圳市健心医疗科技有限公司与国家心血管病中心中国医学科学院阜外医院联合研发的LantvalTM主动脉瓣膜置换系统进入国家药品监督管理局创新医疗器械特别审查程序。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","159883","LNGR","BK1100","PTH","BK1574","09996","BK1600","BK4585","01302","MEDX","BK4588","GDOC","IEIH","AGNG","MDEV","LGHT","HART","BK1583","VXUS","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666127155","title":"【券商聚焦】中信建投：醫療器械板塊業績有望逐步改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2666127155","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666127155?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:18","pubTimestamp":1789089493,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，医疗器械板块Q2收入延续增长趋势，单季度利润增速四年来首次转正。该机构认为，随着集采影响逐步出清叠加创新驱动和海外业务加速的双重助力，医疗器械板块业绩有望逐步改善。尽管季度业绩增速可能有所波动，Q3能否相比Q2加速尚不确定，但大趋势来看，26和27年年度业绩持续改善的确定性较强。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991348","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1589","06826","159883","BK1161","BK1501","BK1615","LNGR","00241","BK1587","HK0000165453.HKD","BK1100","PTH","00853","BK1574","601066","09996","BK1247","BK1600","KCE","BK1189","BK1142","BK1222","01302","BK1502","MEDX","BK1585","BK1593","02190","BK1617","BK1610","GDOC","IEIH","AGNG","02252","02235","MDEV","LGHT","BK1591","HART","LU0173614495.USD","LU0287142896.SGD","BK1583","BK0276","RSPH","BK1571","01066","BK1584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666983512","title":"深港攜手拓全球藥械市場，2026深圳國際高性能醫療器械展舉行","url":"https://stock-news.laohu8.com/highlight/detail?id=2666983512","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666983512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:10","pubTimestamp":1789089045,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["HART","BK1100","BK1583","SG9999003461.SGD","MEDX","GDOC","LU1152091754.HKD","159883","LGHT","LU0880133367.SGD","AGNG","BK1582","LU1152091168.USD","LU0067412154.USD","MDEV","LNGR","LU1008478684.HKD","PTH","BK1574","BK1185","00152","09996","RSPH","IEIH","BK1507"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666917512","title":"【券商聚焦】中信證券：上半年CXO及生命科學上游板塊整體表現穩健，CRO有望量價齊升","url":"https://stock-news.laohu8.com/highlight/detail?id=2666917512","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666917512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:07","pubTimestamp":1789088866,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年上半年，CXO板块及生命科学上游板块整体业绩表现稳健，行业进入复苏阶段。上半年海外投融资景气度持续，美联储加息预期走弱，早研板块整体的景气度持续走强，AIDD的快速发展也将进一步催化未来相关实验和验证需求的爆发，该机构认为CRO板块有望量价齐升。CDMO板块上半年龙头业绩表现稳健，整体订单增速持续加快，行业景气度回升。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991341","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","02268","LU0348827113.USD","BK1574","03933","600030","WX","LU2328871848.SGD","KCE","LU0405327494.USD","06160","02228","IE00B3M56506.USD","BK0196","01099","LU1997245177.USD","SG9999004311.SGD","LU0561508036.HKD","06030","LU1997245094.SGD","02196","LU0463099449.HKD","BK1521","BK0028","LU2778985437.USD","LU0634319403.HKD","01789","LU0244354667.USD","09688","LU1997244956.HKD","09926","LU0348783233.USD","LU1720050803.USD","LU2476274308.USD","LU1188198961.HKD","CXO","BK0188","LU2495084118.USD","LU0417516902.SGD","02367","LU1969619763.USD","BK1500","SG9999014674.SGD","LU1794554557.SGD","06821","LU0540923850.HKD","LU1146622755.USD","BK1100","01530","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666275512","title":"歸創通橋(02190)出現大手買入85萬股，成交價$23.4，涉資1.989千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2666275512","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666275512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:01","pubTimestamp":1789088460,"startTime":"0","endTime":"0","summary":"[大手成交]归创通桥(02190)在上午09:01出现大手买入，成交量为85万，成交价为港币$23.4，涉资1.989千万。至目前为止，股价跌1.277%，今日最高价为$23.4，而最低价为$23.4，总成交量为85万股，总成交金额港币$1.989千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609111/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609111/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1100","BK1583","02190","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666751737","title":"涉IPO操縱嫌疑，香港證監會強制眼科創新藥公司撥康視雲停牌，最牛天使投資人富豪龔虹嘉是站台的基石投資者","url":"https://stock-news.laohu8.com/highlight/detail?id=2666751737","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666751737?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 08:17","pubTimestamp":1789085820,"startTime":"0","endTime":"0","summary":"停牌前，拨康视云报1.19港元，较2025年7月上市发行价10.1港元，累计蒸发约88%。这是一间成立于2015年、专注眼科创新药的临床阶段生物科技公司，四次递表才闯关成功，上市首日即告破发，如今在监管介入调查中股票停牌，前路未卜。证监会表示，调查仍在进行中，暂不作进一步评论。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2026-09-11/doc-inirmfea2271775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","02592","MEDX","06978","FRHC","KCE","BK4127","BK1161","REDS","IPOS","BK1574","LNGR","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666511370","title":"國產創新藥新適應症密集獲批 「一藥拓多域」重塑行業成長邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2666511370","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666511370?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:32","pubTimestamp":1789083145,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06978","BK1161","BK1574","MEDX","159992","IBBQ","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104990066","title":"歐康維視生物-B：OT-301（NCX 470，比馬前列素格倫諾）在華上市申請獲國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1104990066","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104990066?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:13","pubTimestamp":1789081985,"startTime":"0","endTime":"0","summary":"欧康维视生物-B（1477.HK）于9月11日宣布，其核心在研产品OT-301（NCX 470，比马前列素格伦诺）已获中国国家药品监督管理局（NMPA）的新药上市申请（NDA）受理。\n这一进展标志着该创新眼科药物向正式获批上市迈出关键一步。OT-301作为一款新型眼科治疗制剂，其上市申请获得受理，预示着公司有望在中国这一庞大市场中迎来新的增长契机。\n欧康维视生物表示，将继续积极推进OT-301的审评审批进程，力争早日将这一创新疗法带给中国患者。市场分析人士认为，此次NDA获受理对欧康维视生物而言，无疑是一个重要的里程碑事件，有望进一步巩固其在眼科细分领域的竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666197555","title":"歐康維視生物-B(01477)：OT-301新藥上市註冊申請獲國家藥品監督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666197555","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666197555?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:09","pubTimestamp":1789081743,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，OT-301作为降低开角型青光眼或高眼压症患者的眼内压疗法的新药上市注册申请已获中华人民共和国(中国)国家药品监督管理局药品审评中心受理，并获Mont Blanc试验及Denali试验的数据支持。其为一种由Nicox发明的新化学实体，旨在释放贝美前列素及一氧化氮，用于降低开角型青光眼及高眼压症患者的IOP。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01477","IPOS","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666519701","title":"第七批國家組織醫用耗材集中採購開標；諾華大股東呼籲改組董事會｜醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2666519701","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666519701?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:01","pubTimestamp":1789081313,"startTime":"0","endTime":"0","summary":"丨2026年9月11日星期五丨NO.1爱康医疗宣布提高股东股息分派占归母净利比例9月10日，爱康医疗基于对集团未来业绩及长期发展前景的信心，宣布股东股息分派及回报计划，截至2026年12月31日止财政年度，年度股息派付比例提高至不低于归母净利润的55%；截至2027年12月31日及2028年12月31日止财政年度各年，派息比例提升至不低于归母净利润的60%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609113871018788.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609113871018788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","BK4585","BK1515","IE0002141913.USD","BK4532","IE00BJJMRZ35.SGD","NVS","BK4588","IE00B2B36J28.USD","IE00B4R5TH58.HKD","PPH","BK1574","09939","BK4578","MEDX","IE00BFTCPJ56.SGD","LU0208291251.USD","LU0320765489.SGD","IE00BJT1NW94.SGD","LU0070302665.USD","BK4007","IE0009355771.USD","LU0211331839.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666251945","title":"勁方醫藥-B(02595.HK)9月10日斥資206.3萬港元回購8萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666251945","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666251945?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 06:59","pubTimestamp":1789081141,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02595","09939","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666590952","title":"啓明醫療(02500)發新股及換股債集資5億人民幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2666590952","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666590952?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 22:49","pubTimestamp":1789051740,"startTime":"0","endTime":"0","summary":"<汇港通讯>         启明医疗(02500)宣布，建议发行新股及可转换债券，集资5亿元人民币。配售股份约1.845亿股。占扩大后股本约29.5%，配售价每股1.078港元，较9月10日收市价每股1.17港元折让约7.9%，代价1.719亿元人民币。可转换债券本金额3.797亿港元，初步转换价每股1.1858港元，较9月10日收市价溢价约1.4%。认购所得款项总额约5亿元人民币，净额约4.765亿元人民币，其中约25.2%用于支付研发、临床及监管费用；约43.3%补充一般企业营运资金需求；约31.5%用作偿还未偿还贷款。 (WH)新闻来源 (不包括新闻图片): 汇港资讯","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201222151859290_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201222151859290_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/IC4989087/latest-news/INFOCAST","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/IC4989087/latest-news/INFOCAST","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["MUCmain","CYB","BK1574","BK1100","CNHmain","02500","BK1583","MCNHmain","UCmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666594669","title":"同源康醫藥-B(02410.HK)獲董事長吳豫生增持63.5萬股H股 涉資約209萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666594669","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666594669?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 22:47","pubTimestamp":1789051624,"startTime":"0","endTime":"0","summary":"格隆汇9月10日丨同源康医药-B(02410.HK)公告，公司董事长、执行董事兼总裁吴豫生已告知公司，于2026年9月8日至2026年9月10日期间，其于公开市场购入63.5万股公司H股(占公司已发行股本总额约0.17%)，总代价约为209万港元。吴豫生已告知公司，其未来可能继续根据市场情况购买公司股份。目前预计其将在此基础上进一步购买股份的总金额不超过300万港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260910/32366677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1515","BK1161","09939","02410","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":2,"totalSize":342,"code":"91000000","status":"200"}]}}